AstraZeneca (LON:AZN) Stock Price Crosses Above Two Hundred Day Moving Average - Here's What Happened

Key Points

• AstraZeneca's stock price recently surpassed its 200-day moving average, indicating potential upward momentum, with the stock last trading at £113.46.
• Analysts have set target prices for AstraZeneca with Berenberg Bank at £142 and Shore Capital at £135, reflecting a general consensus of a Moderate Buy rating.
• Insider trading activity included Aradhana Sarin selling over 9,500 shares at an average price of £115.12, highlighting some level of confidence or strategy from company executives.

AstraZeneca PLC (LON:AZN - Get Free Report)'s share price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of £109.30 ($147.27) and traded as high as £115.02 ($154.97). AstraZeneca shares last traded at £113.46 ($152.87), with a volume of 3,997,226 shares changing hands.

Analysts Set New Price Targets

Several research firms recently weighed in on AZN. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a £110 target price on shares of AstraZeneca in a report on Wednesday, July 30th. Berenberg Bank reissued a "buy" rating and issued a £142 price target on shares of AstraZeneca in a research report on Monday, September 1st. Finally, Shore Capital reissued a "buy" rating and issued a £135 price target on shares of AstraZeneca in a research report on Tuesday, July 29th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of £131.75.

AstraZeneca Trading Up 0.5%

The firm has a market capitalization of £175.24 billion, a price-to-earnings ratio of 2,128.81, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The business's 50 day moving average price is £113.73 and its 200-day moving average price is £109.17. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59.

Insider Buying and Selling

In related news, insider Aradhana Sarin sold 9,563 shares of the business's stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of £115.12, for a total transaction of £1,100,892.56. Corporate insiders own 0.14% of the company's stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.